KRN5500 Approval Status
- FDA approved: No
- Brand name: KRN5500
- Company: DARA BioSciences, Inc.
- Treatment for: Chronic Chemotherapy Induced Peripheral Neuropathy
KRN5500 is a novel, intravenous, non-opioid, non-narcotic compound in development for the treatment of painful, chronic, chemotherapy-induced peripheral neuropathy (CCIPN) that is refractory to conventional analgesics in patients with cancer.
Development Status and FDA Approval Process for KRN5500
|Jun 16, 2014||DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma|
|Nov 29, 2012||DARA BioSciences Announces Submission of KRN5500 to FDA for Orphan Designation|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.